Loading...
Inozyme Pharma, Inc.
INZY•NASDAQ
Healthcare
Biotechnology
$4.00
$0.010(0.25%)
Inozyme Pharma, Inc. (INZY) Financial Performance & Statements
Review Inozyme Pharma, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
-37.52%
↓ 37.52%
Net Income Growth
-43.35%
↓ 43.35%
Operating Cash Flow Growth
-30.04%
↓ 30.04%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-159.97%
↓ 159.97%
ROIC
-204.98%
↓ 204.98%
Inozyme Pharma, Inc. (INZY) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Inozyme Pharma, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $195000.00 | $188000.00 | $182000.00 |
| Gross Profit | $0.00 | -$195000.00 | -$188000.00 | -$182000.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $22.47M | $19.89M | $21.57M | $19.11M |
| SG&A Expenses | $4.70M | $4.96M | $5.91M | $5.23M |
| Operating Expenses | $27.17M | $24.85M | $27.48M | $24.34M |
| Total Costs & Expenses | $27.17M | $24.85M | $27.66M | $24.34M |
| Interest Income | $1.48M | $1.78M | $2.03M | $2.37M |
| Interest Expense | $1.42M | $1.42M | $1.40M | $1.32M |
| Depreciation & Amortization | $283000.00 | $195000.00 | $188000.00 | $182000.00 |
| EBITDA | -$25.37M | -$22.96M | -$25.45M | -$21.84M |
| EBITDA Ratio | ||||
| Operating Income | -$27.17M | -$24.85M | -$27.66M | -$24.34M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $97000.00 | $281000.00 | $632000.00 | $998000.00 |
| Income Before Tax | -$27.07M | -$24.57M | -$27.03M | -$23.35M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$182000.00 |
| Net Income | -$27.07M | -$24.57M | -$27.03M | -$23.35M |
| Net Income Ratio | ||||
| EPS | -$0.43 | -$0.39 | -$0.44 | -$0.38 |
| Diluted EPS | -$0.43 | -$0.39 | -$0.44 | -$0.38 |
| Weighted Avg Shares Outstanding | $64.24M | $63.28M | $61.94M | $61.77M |
| Weighted Avg Shares Outstanding (Diluted) | $64.24M | $63.28M | $61.94M | $61.77M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan